Oxidative Stress in Alzheimer’s Disease: Should We Keep Trying Antioxidant Therapies?

Cellular and Molecular Neurobiology

Volumn 35, Issue 5, 2015, Pages 595-614

  Ferreira, Michelli Erica Souza ^a   de Vasconcelos, Amanda Soares ^a   da Costa Vilhena, Thyago ^a   da Silva, Thiago Leite ^a   da Silva Barbosa, Aline ^a   Gomes, Antonio Rafael Quadros ^a   Dolabela, Maria Fani ^a   Percário, Sandro ^a  

^a FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

Alzheimer s disease; Amyloid protein; Antioxidants; Free radicals; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; APOLIPOPROTEIN E; ARACHIDONIC ACID; ASCORBIC ACID; CATALASE; CHOLINE ACETYLTRANSFERASE; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; DONEPEZIL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MALONALDEHYDE; MITOCHONDRIAL DNA; PHOSPHATIDYLINOSITOL 3 KINASE; POLYUNSATURATED FATTY ACID; PROTEIN KINASE B; RIVASTIGMINE; SOMATOMEDIN C; SUPEROXIDE DISMUTASE; TACRINE; TAU PROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSITION ELEMENT;

AGING; ALZHEIMER DISEASE; BRAIN CORTEX; CELL MEMBRANE; CELL SURVIVAL; CHOLINERGIC ACTIVITY; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; DISEASE COURSE; ENZYME ACTIVITY; GENE MUTATION; GLUTAMATERGIC SYNAPSE; HIPPOCAMPUS; HUMAN; LIPID PEROXIDATION; LONG TERM POTENTIATION; NERVE CELL; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; ANIMAL; BIOLOGICAL MODEL; DIET SUPPLEMENTATION; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; DIETARY SUPPLEMENTS; HUMANS; MODELS, BIOLOGICAL; OXIDATIVE STRESS;

EID: 84931956706     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-015-0157-y     Document Type: Review

References (224)

1. Adlard PA, Bush AI (2006) Metals and Alzheimer’s disease. J Alzheimers Dis 10:145–163
2. Ahmed HH (2012) Modulatory effects of vitamin E, acetyl-l-carnitine and α-lipoic acid on new potential biomarkers for Alzheimer’s disease in rat model. Exp Toxicol Pathol 64:549–556
3. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF et al (2008) Alzheimer Disease Cooperative Study. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 300:1774–1783
4. Akama KT, Van Eldik LJ (2000) β-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1b- and tumor necrosis factor-α (TNFα)-dependent, and involves a TNFα receptor-associated factor- and NFkB-inducing kinase-dependent signaling mechanism. J Biol Chem 275:7918–7924
5. Akama KT, Albanese C, Pestell RG, Van Eldik LJ (1998) Amyloid-β peptide stimulates nitric oxide production in astrocytes through an NFkB-dependent mechanism. Proc Natl Acad Sci 95:5795–5800
6. Ali FE, Separovic F, Barrow CJ, Cherny RA, Fraser F, Bush AI et al (2005) Methionine regulates copper/hydrogen peroxide oxidation products of A beta. J Pept Sci 11:353–360
7. Ali FE, Leung A, Cherny RA, Mavros C, Barnham KJ, Separovic F et al (2006) Dimerisation of N-acetyl-l-tyrosine ethyl ester and Abeta peptides via formation of dityrosine. Free Radic Res 40:1–9
8. Alzheimer A (1907) Über Eine Eigenartige Erkankung Der Hirnrinde. Allgemeine Z Psychiatrie Psychisch-Gerichtlichen Medizin 64:146–148
9. Alzheimer’s Disease International (2009) World Alzheimer Report 2009. London
10. Ancelin ML, Christen Y, Ritchie K (2007) Is antioxidant therapy a viable alternative for mild cognitive impairment? Examination of the evidence. Dement Geriatr Cogn Disord 24:1–19
11. Arlt S, Muller-Thomsen T, Beisiegel U, Kontush A (2012) Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer’s disease. Neurochem Res 37(12):2706–2714
12. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM et al (1998) Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273:12817–12826
13. Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition and treatment strategies. Prog Neurobiol 68:209–245
14. Bagi Z, Csekó C, Tóth E, Koller A (2003) Oxidative stress-induced dysregulation of arteriolar wall shear stress and blood pressure in hyperhomocysteinemia is prevented by chronic vitamin C treatment. Am J Physiol 285:H2277–H2283
15. Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, Mavros C et al (2004) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer’s disease β-amyloid. FASEB J 18:1427–1429
16. Bartosz G (2009) Reactive oxygen species: destroyers or messengers? J Biochem Pharmacol 77:1303–1315
17. Bartus RT, Emerich DF (1999) Cholinergic markers in Alzheimer disease. JAMA 282(23):2208–2209
18. Batsch NL, Mittelman MS (2012) Overcoming the stigma of dementia. In: Alzheimer’s Disease International, World Alzheimer Report 2012, London
19. Baum L, Lam CWK, Cheung SKK, Kwok T, Lui V, Tsoh J et al (2008) Six-month randomized, placebo controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28(1):110–113
20. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357–366
21. Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite-the good, the bad, and the ugly. Am J Physiol 40:C1424–C1437
22. Behl C (1999) Alzheimer’s disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol 57:301–323
23. Behl C, Moosmann B (2002) Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach. Free Radic Biol Med 33:182–191
24. Behl C, Sagara YR (1997) Mechanism of amyloid beta protein induced neuronal cell death: current concepts and future perspective. J Neural Trasnm Suppl 49:125–134
25. Behl C, Davis J, Cole GM, Schubert D (1992) Vitamin E protects nerve cells from amyloid β-protein toxicity. Biochem Biophys Res Commun 186:944–952
26. Behl C, Davis JB, Lesley R, Schubert D (1994) Hydrogen peroxide mediates amyloid β-protein toxicity. Cell 77:817–822
27. Bierhaus A, Hofman MA, Ziegler R, Nauroth PP (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37:586–600
28. Bigl K, Gaunitz F, Schmitt A, Rothemund S, Schliebs R, Münch G et al (2008) Cytotoxicity of advanced glycation endproducts in human micro- and astroglial cell lines depends on the degree of protein glycation. J Neural Transm 115:1545–1556
29. Bonda DJ, Castellani RJ, Zhu X, Nunomura A, Lee HG, Perry G et al (2011) A novel perspective on tau in Alzheimer disease. Curr Alzheimer Res 8:639–642
30. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, Richard-Harston S, Decamps A, Reigner B et al (2001) Antioxidant defenses and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Aging 30:235–241
31. Bowman GL (2012) Ascorbic acid, cognitive function, and Alzheimer’s disease: a current review and future direction. BioFactors 38:114–122
32. Braak H, Braak E (1991) Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1:213–216
33. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820
34. Buggia-Prevot V, Sevalle J, Rossner S, Checler F (2008) NFkB-dependent control of BACE1 promoter transactivation by Aβ42. J Biol Chem 283:10037–10047
35. Butterfield DA, Kanski J (2002) Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer’s amyloid β-peptide 1–42. Peptides 23:1299–1309
36. Byun K, Bayarsaikhan E, Kim D, Kim CY, Mook-Jung I, Paek SH et al (2012a) Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer’s disease. PLoS One 7(5):e37917
37. Byun K, Bayarsaikhan E, Kim D, Son M, Hong J, Jeong GB et al (2012b) Activated microglial cells synthesize and secrete AGE-albumin. Anat Cell Biol 45:47–52
38. Cai X, Golde T, Younkin S (1993) Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 259:514–516
39. Cappai R, Barnham KJ (2007) Molecular determinants of Alzheimer’s disease Abeta peptide neurotoxicity. Future Neurol 2:397–409
40. Caramelli P, Barbosa MT (2002) Como diagnosticar as quatro causas mais frequentes de demência? Rev Bras Psiquiatr 24:7–10
41. Carubelli R, Schneider JE Jr, Pye QN, Floyd RA (1995) Cytotoxic effects of autoxidative glycation. Free Radic Biol Med 18:265–269
42. Castellani RJ, Lee H, Perry G, Smith MA (2006) Antioxidant protection and neurodegenerative disease: the role of amyloid-f3 and tau. Am J Alzheimers Dis Other Demen 21:126–130
43. Cente M, Filipcik P, Pevalova M, Novac M (2006) Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy. Eur J Neurosci 24:1085–1090
44. Chai GS, Jiang X, Ni ZF, Ma ZW, Xie AJ, Cheng XS et al (2013) Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. J Neurochem 124:388–396
45. Chan A, Remington R, Kotyla E, Lepore A, Zemianek J, Shea TB (2010) A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. J Nutr Health Aging 14(3):224–230
46. Chen L, Richardson JS, Caldwell JE, Ang LC (1994) Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer’s disease and from nondemented controls. Int J Neurosci 75:83–90
47. Chen K, Kazachkov M, Yu PH (2007a) Effect of aldehydes derived from oxidative deamination and oxidative stress on beta-amyloid aggregation; pathological implications to Alzheimer’s disease. J Neural Transm 114:835–839
48. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD (2007b) RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer’s disease. Curr Mol Med 7:735–742
49. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS et al (1999) Aqueous dissolution of Alzheimer’s disease abeta amyloid deposits by biometal depletion. J Biol Chem 274:23223–23228
50. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA et al (2001) Treatment with a copper zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 30:665–676
51. Christen Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71:621S–629S
52. Clauberg M, Joshi JG (1993) Regulation of serine protease activity by Al: implications for Alzheimer disease. Proc Natl Acad Sci USA 90:1009–1012
53. Combs CK, Karlo JC, Kao S, Landreth GE (2001) β-amyloid stimulation of microglia and monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21:1179–1188
54. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785–789
55. Cruz-Sánchez FF, Gironès X, Ortega A, Alameda F, Lafuente JV (2010) Oxidative stress in Alzheimer’s disease hippocampus: a topographical study. J Neurol Sci 299:163–167
56. Cummings JL, McRae T, Zhang R (2006) Donepezil-Sertraline Study Group. Effects of donepezil on neuropsyquiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 14:605–612
57. Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K et al (2001) Alzheimer’s disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 276:20466–20473
58. Dai X, Sun Y, Jiang Z (2006) Cu (II) potentiation of alzheimer Aβ1-40 cytotoxicity and transition on its secondary structure. Acta Biochim Biophys Sinica 38:765–772
59. Danscher G, Stoltenberg M (2005) Zinc-specific autometallographic in vivo selenium methods: tracing of zinc-enriched (ZEN) terminals, ZEN pathways, and pools of zinc ions in a multitude of other ZEN cells. J Histochem Cytochem 53:141–153
60. De Strooper D, Saftig P, Craessmaerts K (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387–390
61. Disilvestro RA, Joseph E, Zhao S, Bomser J (2012) Diverse effects of a low dose supplement of lapidated curcumin in healthy middle aged people. Nutr J 11:79
62. Drechsel DN, Hyman AA, Cobb MH, Kirschnner MW (1992) Modulation of the dynamic instability of tubulin assembly by microtubule-associated protein tau. Mol Cell Biol 10:1141–1154
63. El-Agamey A, Lowe GM, McGarvey DJ, Mortensen A, Phillip DM, Truscott TG et al (2004) Carotenoid radical chemistry and antioxidant/pro-oxidant properties. Arch Biochem Biophys 430:37–48
64. Feng Y, Wang X (2012) Antioxidant therapies for Alzheimer’s disease. Oxid Med Cell Longev ID472932
65. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M et al (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117
66. Forbes JM, Soldatos G, Thomas MC (2005) Below the radar: advanced glycation end products that detour “around the side”. Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes? Clin Biochem Rev 26:123–134
67. Forlenza OV (2005) Tratamento Farmacológico da Doença de Alzheimer. Rev Psiq Clín 32:137–148
68. Frederickson CJ, Koh JY, Bush AI (2005) The neurobiology of zinc in health and disease. Nat Rev Neurosci 6:449–462
69. Frederickson CJ, Giblin LJ III, Balaji RV, Masalha R, Frederickson CJ, Zeng Y et al (2006) Synaptic release of zinc from brain slices: factors governing release, imaging, and accurate calculation of concentration. J Neurosci Methods 154(1–2):19–29
70. Friedlich AL, Butcher LL (1994) Involvement of free oxygen radicals in beta-amyloidosis: a hypothesis. Neurobiol Aging 15:443–455
71. Friedlich AL, Lee JY, Van Groen T, Cherny RA, Volitakis I, Cole TB et al (2004) Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer’s disease. J Neurosci 24:3453–3459
72. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA et al (2012) Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69(7):836–841
73. Gasic-Milenkovic J, Loske C, Munch G (2003) Advanced glycation endproducts cause lipid peroxidation in the human neuronal cell line SH-SY5Y. J Alzheimers Dis 5:25–30
74. Gattaz WF, Forlenza OV, Talib LL, Barbosa NR, Bottino CM (2004) Platelet phospholipase A2 activity in Alzheimer´s disease and mild cognitive impairment. J Neural Transm 111:591–601
75. Glenner GG (1988) Alzheimer’s disease: its proteins and genes. Cell 52:307–308
76. Golde TE (2006) Disease modifying therapy for AD? J Neurochem 3:689–707
77. Goodman Y, Mattson MP (1994) Secreted forms of β-amyloid precursor protein protect hippocampal neurons against amyloid β-peptide-induced oxidative injury. Exp Neurol 128:1–12
78. Goodman Y, Steiner M, Steiner S, Mattson MP (1994) Nordihydroguaiaretic acid protects hippocampal neurons against amyloid β-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res 654:171–176
79. Graeber MB, Kosel S, Grasbon-Frodi E, Moller HJ, Mehraein P (1998) Histopathology and APOE genotype of the first Alzheimer disease patient, Auguste D. Neurogenetics 1:223–228
80. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3 beta in cellular signaling. Prog Neurobiol 65:391–426
81. Grodstein F, Chen J, Willet WC (2003) High dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am J Clin Nutr 77:975–984
82. Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K, Joshi JG (1990) Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol 81:105–110
83. Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I et al (1995) Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64:1216–1223
84. Guix FX, Raga Ill G, Bravo R, Nakaya T, Fabritiis G, Coma M et al (2009) Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation. Brain J Neurol 132:1335–1345
85. Hager K, Kenklies M, McAfoose J, Engel J, Munch G (2007) Alpha-lipoic acid as a new treatment option for Alzheimer’s disease a 48 months follow-up analysis. J Neural Transm Suppl 72:189–193
86. Halliwell B, Gutteridge JMC (2007) Free radicals in biology and medicine, 3rd edn. Oxford University Press, New York
87. Hardy J (1997) Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 20:154–159
88. Harman D, Eddy DE, Noffsinger J (1976) Free radical theory of aging: inhibition of amyloidosis in mice by antioxidants: possible mechanism. J Am Geriatr Soc 24:203–210
89. Hazel JR, Williams EE (1990) The role of alterations in membrane lipid composition in enabling physiological adaptation of organisms to their physical environment. Prog Lipid Res 29:167–227
90. Helson L (1984) The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors. Thromb Res 35:11–18
91. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M et al (1995) Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J Neurochem 65:2146–2156
92. Hernandez F, Avila J (2007) Tauopathies. Cell Mol Life Sci 64:2219–2233
93. Hidalgo FJ, Zamora R (2005) Interplay between the maillard reaction and lipid peroxidation in biochemical systems. Ann N Y Acad Sci 1043:284–289
94. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR et al (1999) Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274:37111–37116
95. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT (2004) Redox-active metals, oxidative stress, and Alzheimer’s disease pathology. Ann N Y Acad Sci 1012:153–163
96. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE (2006) Diabetes and glicoxidation end products. Diabetes Care 29:1420–1432
97. Hutton M, Busfield F, Wragg M, Crook R, Pérez-Tur J, Clark RF (1996) Complete analysis of the presenilin 1 gene in early onset Alzheimer’s disease. Neuroreport 7:801–805
98. Hyman BT, Van Hoesen GW, Damasio AR (1990) Memory-related neural systems in Alzheimer’s disease: an anatomic study. Neurology 40:1721–1730
99. Ikeda T, Yamamoto K, Takahashi K (1992) Treatment of Alzheimer-type dementia with intravenous mecobalamin. Clin Ther 14:426–437
100. Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM et al (2009) Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer’s type (SDAT). Eur Neuropsychopharmacol 19:636–647
101. Ittner LM, Gotz J (2011) Amyloid-β and tau—a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci 12:67–72
102. Jakus V, Rietbrock N (2004) Advanced glycation end products and the progress of diabetic vascular complications. Physiol Res 53:131–142
103. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH et al (1987) The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733–736
104. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA et al (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64:1152–1156
105. Kim H, Evans I, Smallwood R, Holcombe M, Qwamstrom EE (2010) NIK and IKK interdependence in NF-kB signaling-flux analysis of regulation. J Biosyst 99:140–149
106. Kimura T, Takamatsu J, Araki N, Goto M, Kondo A, Miyakawa T et al (1995) Are advanced glycation end-products associated with amyloidosis in Alzheimer’s disease? Neuroreport 6:866–868
107. Kovac A, Zilka N, Kazmerova Z, Cente M, Zilkova M, Novac M (2011) Misfolded truncated protein τ induces innate immune response via MAPK pathway. J Immunol 187:2723–2739
108. Kriete A, Mayo KL (2009) Atypical pathways of NF-kB activation and aging. J Exp Gerontol 44:250–255
109. Kuhla B, Loske C, De Arriba SG, Schinzel R, Huber J, Münch G (2004) Differential effects of “advanced glycation endproducts” and β-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J Neural Transm 111:427–439
110. Lanctôt KL, Herrmann N, Loulou MM (2003) Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer´s disease. J Psychiatry Neurosci 28:13–26
111. Lapolla A, Fedele D, Traldi P (2005) Glyco-oxidation in diabetes and related diseases. Clin Chim Acta 357:236–250
112. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci USA 99:7705–7710
113. Leslie RD, Beyan H, Sawtell P, Boehm BO, Spector TD, Snieder H (2003) Level of an advanced glycated end product is genetically determined. A study of normal twins. Diabetes 52:2441–2444
114. Li X, Song L, Jope RS (1996) Cholinergic stimulation of AP-1 and NFKB transcription factors is differentially sensitive to oxidative stress in sh-sy5y neuroblastoma: relationship to phosphoinositide hydrolysis. J Neurosci 16:5914–5922
115. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21:8370–8377
116. Lin L (2006) RAGE on the toll road? Cell Mol Immunol 3:351–358
117. Lo ACY, Haass C, Wagner SL, Teplow DB, Sisodia SS (1994) Metabolism of the “Swedish” amyloid precursor protein variant in Madin-Darby canine kidney cells. J Biol Chem 269:22099–22104
118. Lohr JB (1991) Oxygen radicals and neuropsychiatric illness. Arch Gen Psychiatry 48:1097–1106
119. Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated thiobarbituric acid reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology 45:1594–1601
120. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998a) Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 158:47–52
121. Lovell MA, Xie C, Markesbery WR (1998b) Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer’s disease. Neurology 51:1562–1566
122. Lowenberg K, Waggoner R (1934) Familial organic psychosis (Alzheimer’s type). Arch Neurol Psychiatry 31:737–754
123. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM et al (2001) Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism. Exp Neurol 171:29–45
124. Mann DMA (1985) The neuropathology of Alzheimer’s disease: a review with pathogenetic, aetiological and therapeutic considerations. Mech Ageing 31:213–255
125. Marcus DL, Thomas C, Rodríguez C, Simberkoff K, Tsai JS, Strafaci JA et al (1998) Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer’s disease. Exp Neurol 150:40–44
126. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 58:730–735
127. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H et al (2000) Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 54:1265–1272
128. McCaddon A, Hudson P, Hill D, Barber J, Lloyd A, Davies G et al (2003) Alzheimer’s disease and total plasma aminothiols. Biol Psychiatry 53:254–260
129. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM (2006) A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 354:2764–2772
130. Meade SJ, Miller AG, Gerrard JA (2003) The role of dicarbonyl compounds in non-enzymatic crosslinking: a structure–activity study. Bioorg Med Chem 11:853–862
131. Mecocci P, MacGarvey U, Beal MF (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol 36:747–751
132. Monnier VM (2003) Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 419:1–15
133. Moreira PI, Harris PL, Zhu X, Santos MS, Oliveira CR, Smith MA et al (2007) Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis 12:195–206
134. Morris RG, Salmon DP (2007) The centennial of Alzheimer’s disease and the publication of “Über Eine Eigenartige Erkankung Der Hirnrinde” by Alois Alzheimer. Cortex 43:821–825
135. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS (2002) Vitamin E and cognitive decline in older persons. Arch Neurol 59:1125–1132
136. Mullarkey CJ, Edelstein D, Brownlee M (1990) Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173:932–939
137. Muller WE, Kosh S, Eckert A, Hartmann H, Scheuer K (1995) β-amyloid peptide decreases membrane fluidity. Brain Res 674:33–36
138. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al (2000) Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. JAMA 283(8):1007–1015
139. Munch G, Thorne J, Foley P, Schinzel R, Riederer P (1997) Advanced glycation end products in aging and Alzheimer’s disease. Brain Res Rev 23:134–143
140. Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ et al (1998) Alzheimer’s disease synergistic effects of glucose deficit: oxidative stress and advanced glycation endproducts. J Neural Transm 105:439–461
141. Münch G, Deuther-Conrad W, Gasic-Milenkovic J (2002) Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer’s disease a target for neuroprotective treatment strategies? J Neural Transm 62:303–307
142. 2 production. Mol Nutr Food Res 51:525–535
143. Nitrini R (1999) Epidemiologia da doença de Alzheimer no Brasil. Rev Psiquiatr Clin 26:262–267
144. Nitsch RM, Slack BE, Farber SA, Schulz JG, Deng M, Kim C et al (1994) Regulation of proteolytic processing of the amyloid β-protein precursor of Alzheimer’s disease in transfected cell lines and in brain slices. J Neural Transm 44:21–27
145. Ortwerth BJ, James H, Simpson G, Linetsky M (1998) The generation of superoxide anions in glycation reactions with sugars, ozone, and 3-deoxyosones. Biochem Biophys Res Commun 245:161–165
146. Packer MA, Murphy MP (1994) Peroxynitrite causes efflux from mitochondria which is prevented by cyclosporin A. FEBS Lett 345:237–240
147. Packer MA, Scarlett JL, Martin SW, Murphy MP (1997) Induction of the mitochondrial permeability transition by peroxynitrite. Biochem Soc Trans 25:909–914
148. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C (2010) Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer’s disease. Neurosci Lett 469:6–10
149. Payami H, Kaye J, Heston LL, Bird TD, Schellenberg GD (1993) Apolipoprotein E genotypes and Alzheimer’s disease. Lancet 342:737–738
150. Peppa M, Uribarri J, Vlassara H (2003) Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clin Diabetes 21:186–187
151. Perkins AJ, Hendrie HC, Callahan CM, Gao S, Unverzagt FW, Xu Y et al (1999) Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am J Epidemiol 150:37–44
152. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 25:1457–1459
153. Persson T, Popescu BO, Cedazo-Minguez A (2014) Oxidative stress in Alzheimer’s disease: why did antioxidant therapy fail. Oxid Med Cell Longev ID427318
154. Perumal AS, Gopal VB, Tordzro WK, Cooper TB, Cadet JL (1992) Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 29:699–701
155. Prasad KN, Cole WC, Prasad KC (2002) Risk factors for Alzheimer’s disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J Am Coll Nutr 21:506–522
156. Pratico D, Sung S (2004) Lipid peroxidation and oxidative imbalance: early functional event in Alzheimer’s disease. J Alzheimers Dis 6:171–175
157. Pratico D, Clark CM, Liun F, Lee VY, Trojanowsk JQ (2002) Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 59:972–976
158. Price DL (1986) New perspectives on Alzheimer’s disease. Annu Rev Neurosci 9:489–512
159. Prince M, Bryce R, Ferri C (2011) The benefits of early diagnosis and intervention, executive summary. In: Alzheimer’s Disease International, World Alzheimer Report 2011, London
160. Quinn JF, Bussiere JR, Hammond RS, Montine TJ, Henson E, Jones RE et al (2007) Chronic dietary α-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 28:213–215
161. Quintana C, Bellefqih S, Laval JY, Guerquin-Kern JL, Wu TD, Avila J et al (2006) Study of the localization of iron, ferritin, and hemosiderin in Alzheimer’s disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol 153:42–54
162. Rao KSJ, Rao RV, Shanmugavelu P, Menon RB (1999) Trace elements in Alzheimer’s disease brain: a new hypothesis. Alzheimers Rep 2:241–246
163. Reddy PH (2011) Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer’s disease. Brain Res 1415:136–148
164. Regland B, Gottfries CG, Oreland L (1991) Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia. Eur Arch Psychiatry Clin Neurosci 240:288–291
165. Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, Winblad B et al (2006) Elevated cortical zinc in Alzheimer disease. Neurology 67:69–75
166. Richter T, Munch G, Luth HJ, Arendt T, Kientsch-Engel R, Stahl P et al (2005) Immunochemical crossreactivity of antibodies specific for “advanced glycation end products” with “advanced lipoxidation endproducts”. Neurobiol Aging 26:465–474
167. Rinaldi P, Polidori MC, Metasstasio A (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer’s disease. Neurobiol Aging 24:915–919
168. Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beiji M et al (2012) Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double-blind, placebo-controlled study. Alzheimers Res Ther 4(5):43
169. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L et al (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer’s disease: biochemical and clinical responses in a pilot phase 2 clinical trial. Arch Neurol 60:1685–1691
170. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H et al (2002) An iron-responsive element type II in the 5′ untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem 277:45518–45528
171. Russ C, Lovestone S, Powell JF (2001) Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer´s disease. Mol Psychiatry 6:320–324
172. Sagara YR, Dargusch R, Klier FG, Schubert D, Behl C (1996) Increased antioxidant enzyme activity in amyloid beta protein-resistant cells. J Neurosci 16:497–505
173. Saitoh T, Sundsmo M, Roch J, Ximura M, Cole G, Schubert D et al (1989) Secreted form of amyloid β-protein precursor is involved in the growth regulation of fibroblasts. Cell 58:615–622
174. Sano M, Ernesto C, Thomas RG (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336:1216–1222
175. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M (2006) Toxic advanced glycation end products (TAGE) theory in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2:197–208
176. Schlief ML, Craig AM, Gitlin JD (2005) NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J Neurosci 25:239–246
177. Schlief ML, West T, Craig AM, Holtzman DM, Gitlin JD (2006) Role of the Menkes copper-transporting ATPase in NMDA receptor mediated neuronal toxicity. Proc Natl Acad Sci USA 103:14919–14924
178. Schubert D, Jin LW, Saitoh T, Cole G (1989) The regulation of amyloid β-protein precursor secretion and its modulatory role in cell adhesion. Neuron 3:689–694
179. Schubert D, Kimura H, Maher P (1992) Growth factors and vitamin E modify neuronal glutamate toxicity. Proc Natl Acad Sci USA 89:8264–8267
180. Selkoe DJ (1993) Physiological production of the β-amyloid protein and the mechanism of Alzheimer’s disease. Trends Neurosci 16:403–409
181. Sherrington RE, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375:754–760
182. Siedlak SL, Casadesus G, Webber KM, Pappolla MA, Atwood CS, Smith MA et al (2009) Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer’s disease. Free Radic Res 43:156–164
183. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SRJ (1998) Altered plasma antioxidant status in subjects with Alzheimer’s disease and vascular dementia. Int J Geriatr Psychiatry 13:840–845
184. Sinha M, Saha A, Basu S, Pal K, Chakrabarti S (2010) Aging and antioxidants modulate rat brain levels of homocysteine and dehydroepiandrosterone sulphate (DHEA-S): implications in the pathogenesis of Alzheimer’s disease. Neurosci Lett 483:123–126
185. Smith MA, Perry G (1994) Alzheimer disease: an imbalance of proteolytic regulation? Med Hypotheses 42:277–279
186. Smith MA, Sayre LM (1995) Radical AGEing in Alzheimer disease. Trends Neurosci 18:172–176
187. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA et al (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc Natl Acad Sci USA 88:10540–10543
188. Smith MA, Petot GJ, Perry G (1999) Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer’s disease. J Alzheimers Dis 1:203–206
189. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D et al (2011) Advanced glycation end products and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging 32:763–777
190. St George-Hyslop P (1995) Genetic determinants of Alzheimer disease. Prog Clin Biol Res 393:139–145
191. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM (2002) Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 156:1051–1063
192. Stocker R (1994) Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr Opin Lipidol 5:422–433
193. Subbarao KV, Richardson JS, Ang LC (1990) Autopsy samples of Alzheimer’s cortex show increased peroxidation in vitro. J Neurochem 55:342–345
194. Suchy J, Chan A, Shea TB (2009) Dietary supplementation with a combination of α-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance. Nutr Res 29:70–74
195. Suh Y, Checler F (2002) Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer’s disease. Pharmacol Rev 54:469–525
196. Sultan A, Nesslany F, Violet M, Bégard S, Loyens A, Talahari S et al (2011) Nuclear tau, a key player in neuronal DNA protection. J Biol Chem 286:4566–4575
197. Sultana R, Mecocci P, Mangialasche F, Cecchetti R, Baglioni M, Butterfield A (2011) increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer’s disease: insights into the role of oxidative stress in Alzheimer’s disease and initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis 24:77–84
198. Sung S, Yao Y, Uryu K, Yang H, Lee VMY, Trojanowski JQ et al (2004) Early Vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer’s disease. FASEB J 18(2):323–325
199. Takeuchi M, Yamagishi S (2004) TAGE (toxics AGEs) hypothesis in various chronic diseases. Med Hypotheses 63:449–452
200. Takeuchi M, Sato T, Takino J, Kobayashi Y, Furuno S, Kikuchi S et al (2007) Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer’s disease. Med Hypotheses 69:1358–1366
201. Tanzi RE, Kovacs DM, Kim TW, Moir RD, Guenette SY, Wasco W (1996) The gene defects responsible for familial Alzheimer’s disease. Neurobiol Dis 3:159–168
202. Terry RD (1985) Alzheimer’s disease. In: Davis RL, Robertson DM (eds) Textbook of neuropathology. Williams and Wilkins, Baltimore, pp 824–841
203. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) Beta-amyloid mediated vasoactivity and vascular endothelial damage. Nature 380:168–171
204. Thornalley PJ (2003) The enzymatic defense against glycation in health, disease and therapeutics: a symposium to examine the concept. Biochem Soc Trans 6:1341–1342
205. Truzzi A, Laks J (2005) Doença de Alzheimer esporádica de início precoce. Rev Psiquiatr Clín 32(1):43–46
206. Uwano C, Suzuki M, Aikawa T, Ebihara T, Une K, Tomita N et al (2012) Rivastigmine dermal patch solves eating problems in an individual with advanced Alzheimer’s disease. J Am Geriatr Soc 60(10):1979–1980
207. Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N (2010) Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis 37:67–76
208. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J (2004) Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 266:37–56
209. Valla J, Berndt JD, Gonzalez-Lima F (2001) Energy hypometabolism in posterior cingulated cortex of Alzheimer’s patients: superficial laminar cytochrome oxidase associated with disease duration. J Neurosci 21:4923–4930
210. Vas CJ, Rajikumar S, Tanyakitpisal P, Chandra V (2001) Alzheimer’s disease: the brain killer. World Health Organization, Regional Office for South-East Asia, New Delhi
211. Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B et al (2012) Long term use of standardized ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomized placebo-controlled trial. Lancet Neurol 11(10):851–859
212. Vlassara H, Palace MR (2002) Diabetes and advanced glycation end products. J Intern Med 251:87–101
213. Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S et al (2002) High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 277:4644–4648
214. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle AW, Delon MR (1982) Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237–1239
215. Wimo A, Prince M (2010) The global economic impact of dementia. In: Alzheimer’s Disease International, World Alzheimer Report 2010, London
216. Xue J, Rai V, Frolov S, Singer D, Chabierski S, Xie J et al (2011) Advanced glycation end product (AGE) recognition by the receptor for AGEs (RAGE). Structure 19:722–732
217. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS et al (1994) Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 91:7787–7791
218. Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F et al (1997) An intracellular protein that binds amyloid-betapeptide and mediates neurotoxicity in Alzheimer’s disease. Nature 389:689–695
219. Yang SG, Wang WY, Ling TJ, Feng Y, Du XT, Zhang X et al (2010) α-Tocopherol quinone inhibits β-amyloid aggregation and cytotoxicity, disaggregates preformed fibrils and decreases the production of reactive oxygen species, NO and inflammatory cytokines. Neurochem Int 57:914–922
220. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H (2005) Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci 97:305–311
221. Zafrilla P, Mulero J, Xandri JM, Santo E, Caravaca G, Morillas JM (2006) Oxidative stress in Alzheimer patients in different stages of the disease. Curr Med Chem 13:1075–1083
222. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863–873
223. Zhu X, Raina AK, Perry G, Smith MA (2004) Alzheimer’s disease: the two-hit hypothesis. Lancet Neurol 3:219–226
224. Zinser EG, Hartmann T, Grimm MOW (2007) Amyloid beta-protein and lipid metabolism. Biochem Biophys Acta 1768:1991–2001